Simon Villegas-Ospina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Simon Villegas-Ospina has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Karyn N. Johnson
School of the Environment, The University of Queensland
2 shared publications - Wbeimar Aguilar-Jimenez
Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia
2 shared publications - Wildeman Zapata
Grupo Infettare, Facultad de Medicina, Universidad Cooperativa de Colombia, Medellín, Colombia
2 shared publications - Angelique K. Asselin
School of the Environment, The University of Queensland, Brisbane, QLD, 4072, Australia
1 shared publication - Ary Anthony Hoffmann
Pest and Environmental Adaptation Research Group, Bio21 Institute, University of Melbourne, Melbourne, Victoria 3052, Australia
1 shared publication - David John Merritt
ASchool of the Environment, The University of Queensland, Brisbane, Qld 4072, Australia
1 shared publication
Latest Publications
- Open Access
Physical and Chemical Barriers in the Larval Midgut Confer Developmental Resistance to Virus Infection in Drosophila
Insects can become lethally infected by the oral intake of a number of insect-specific viruses. Virus infection commonly occurs in larvae, given their active feeding behaviour; however, older larvae often become resistant to oral viral infections. To investigate mechanisms that contribute to resistance throughout the larval development, we orally challenged Drosophila larvae at different stages of their development with Drosophila C virus (DCV, Dicistroviridae). Here, we showed that DCV-induced mortality is highest when infection initiates early in larval development and decreases the later in development the infection occurs. We then evaluated the peritrophic matrix as an antiviral barrier within the gut using a Crystallin-deficient fly line (Crys−/−), whose PM is weakened and becomes more permeable to DCV-sized particles as the larva ages. This phenotype correlated with increasing mortality the later in development oral challenge occurred. Lastly, we tested in vitro the infectivity of DCV after incubation at pH conditions that may occur in the midgut. DCV virions were stable in a pH range between 3.0 and 10.5, but their infectivity decreased at least 100-fold below (1.0) and above (12.0) this range. We did not observe such acidic conditions in recently hatched larvae. We hypothesise that, in Drosophila larvae, the PM is essential for containing ingested virions separated from the gut epithelium, while highly acidic conditions inactivate the majority of the virions as they transit.
Open AccessPhysical and Chemical Barriers in the Larval Midgut Confer Developmental Resistance to Virus Infection in Drosophila
Insects can become lethally infected by the oral intake of a number of insect-specific viruses. Virus infection commonly occurs in larvae, given their active feeding behaviour; however, older larvae often become resistant to oral viral infections. To investigate mechanisms that contribute to resistance throughout the larval development, we orally challenged Drosophila larvae at different stages of their development with Drosophila C virus (DCV, Dicistroviridae). Here, we showed that DCV-induced mortality is highest when infection initiates early in larval development and decreases the later in development the infection occurs. We then evaluated the peritrophic matrix as an antiviral barrier within the gut using a Crystallin-deficient fly line (Crys−/−), whose PM is weakened and becomes more permeable to DCV-sized particles as the larva ages. This phenotype correlated with increasing mortality the later in development oral challenge occurred. Lastly, we tested in vitro the infectivity of DCV after incubation at pH conditions that may occur in the midgut. DCV virions were stable in a pH range between 3.0 and 10.5, but their infectivity decreased at least 100-fold below (1.0) and above (12.0) this range. We did not observe such acidic conditions in recently hatched larvae. We hypothesise that, in Drosophila larvae, the PM is essential for containing ingested virions separated from the gut epithelium, while highly acidic conditions inactivate the majority of the virions as they transit.
- 1 March 2019
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 85 (5)
Contrasting Patterns of Virus Protection and Functional Incompatibility Genes in Two ConspecificWolbachiaStrains fromDrosophila pandora
Wolbachiastrains are common endosymbionts in insects, with multiple strains often coexisting in the same species. The coexistence of multiple strains is poorly understood but may rely onWolbachiaorganisms having diverse phenotypic effects on their hosts. AsWolbachiais increasingly being developed as a tool to control disease transmission and suppress pest populations, it is important to understand the ways in which multipleWolbachiastrains persist in natural populations and how these might then be manipulated. We have therefore investigated viral protection and the molecular basis of cytoplasmic incompatibility in two coexistingWolbachiastrains with contrasting effects on host reproduction.
- 1 March 2019
- Published by American Society for Microbiology in Applied and Environmental Microbiology
- Vol. 85 (5)
Contrasting Patterns of Virus Protection and Functional Incompatibility Genes in Two ConspecificWolbachiaStrains fromDrosophila pandora
Wolbachiastrains are common endosymbionts in insects, with multiple strains often coexisting in the same species. The coexistence of multiple strains is poorly understood but may rely onWolbachiaorganisms having diverse phenotypic effects on their hosts. AsWolbachiais increasingly being developed as a tool to control disease transmission and suppress pest populations, it is important to understand the ways in which multipleWolbachiastrains persist in natural populations and how these might then be manipulated. We have therefore investigated viral protection and the molecular basis of cytoplasmic incompatibility in two coexistingWolbachiastrains with contrasting effects on host reproduction.
- 1 June 2017
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 37 (2) , 267-273
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort
- 1 June 2017
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 37 (2) , 267-273
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort
Haplotypes in CCR5-CCR2, CCL3 and CCL5 are associated with natural resistance to HIV-1 infection in a Colombian cohort
- 15 December 2016
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 73 (5) , 497-506
Precursor Forms of Vitamin D Reduce HIV-1 Infection In Vitro
Background: Although the anti-HIV-1 effects of vitamin D (VitD) have been reported, mechanisms behind such protection remain largely unexplored. Methods: The effects of two precursor forms (cholecalciferol/calciol at 0.01, 1 and 100 nM and calcidiol at 100 and 250 nM) on HIV-1 infection, immune activation, and gene expression were analyzed in vitro in cells of Colombian and Italian healthy donors. We quantified levels of released p24 by enzyme-linked immunosorbent assay, of intracellular p24 and cell-surface expression of CD38 and HLA-DR by flow cytometry, and mRNA expression of antiviral and immunoregulatory genes by real-time reverse transcription-polymerase chain reaction. Results: Cholecalciferol decreased the frequency of HIV-1-infected p24+CD4+ T cells and levels of p24 in supernatants in a dose-dependent manner. Moreover, the CD4+CD38+HLA-DR+ and CD4+CD38−HLA-DR+ subpopulations were more susceptible to infection but displayed the greatest cholecalciferol-induced decreases in infection rate by an X4-tropic strain. Likewise, cholecalciferol at its highest concentration decreased the frequency of CD38−HLA-DR+ but not of CD38+HLA-DR+ T-cell subsets. Analyzing the effects of calcidiol, the main VitD source for immune cells and an R5-tropic strain as the most frequently transmitted virus, a reduction in HIV-1 productive infection was also observed. In addition, an increase in mRNA expression of APOBEC3G and PI3 and a reduction of TRIM22 and CCR5 expression, this latter positively correlated with p24 levels, was noted. Conclusions: VitD reduces HIV-1 infection in T cells possibly by inducing antiviral gene expression, reducing the viral co-receptor CCR5 and, at least at the highest cholecalciferol concentration, by promoting an HIV-1-restrictive CD38+HLA-DR− immunophenotype.
- 15 December 2016
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 73 (5) , 497-506
Precursor Forms of Vitamin D Reduce HIV-1 Infection In Vitro
Background: Although the anti-HIV-1 effects of vitamin D (VitD) have been reported, mechanisms behind such protection remain largely unexplored. Methods: The effects of two precursor forms (cholecalciferol/calciol at 0.01, 1 and 100 nM and calcidiol at 100 and 250 nM) on HIV-1 infection, immune activation, and gene expression were analyzed in vitro in cells of Colombian and Italian healthy donors. We quantified levels of released p24 by enzyme-linked immunosorbent assay, of intracellular p24 and cell-surface expression of CD38 and HLA-DR by flow cytometry, and mRNA expression of antiviral and immunoregulatory genes by real-time reverse transcription-polymerase chain reaction. Results: Cholecalciferol decreased the frequency of HIV-1-infected p24+CD4+ T cells and levels of p24 in supernatants in a dose-dependent manner. Moreover, the CD4+CD38+HLA-DR+ and CD4+CD38−HLA-DR+ subpopulations were more susceptible to infection but displayed the greatest cholecalciferol-induced decreases in infection rate by an X4-tropic strain. Likewise, cholecalciferol at its highest concentration decreased the frequency of CD38−HLA-DR+ but not of CD38+HLA-DR+ T-cell subsets. Analyzing the effects of calcidiol, the main VitD source for immune cells and an R5-tropic strain as the most frequently transmitted virus, a reduction in HIV-1 productive infection was also observed. In addition, an increase in mRNA expression of APOBEC3G and PI3 and a reduction of TRIM22 and CCR5 expression, this latter positively correlated with p24 levels, was noted. Conclusions: VitD reduces HIV-1 infection in T cells possibly by inducing antiviral gene expression, reducing the viral co-receptor CCR5 and, at least at the highest cholecalciferol concentration, by promoting an HIV-1-restrictive CD38+HLA-DR− immunophenotype.
- 14 July 2016
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 29 (3) , 93-103
Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells
Objective: Vitamin D (VitD) is an anti-inflammatory hormone; however, some evidence shows that VitD may induce the expression of activation markers, such as CD38 and HLA-DR. We explored its effect on the expression of these markers on CD4 + and CD8 + T-cells in vitro, and their potential correlations in vivo. Materials and methods: CD38 and HLA-DR expression was measured by flow cytometry in PHA/IL-2-activated mononuclear cells cultured under VitD precursors: three cholecalciferol (10 −11 M, 10 −9 M, 10 −7 M; n=11) and two calcidiol (40 ng/mL, 80 ng/mL; n=9) concentrations. The correlation between the expression of these markers in freshly isolated blood cells and serum levels of calcidiol was also explored (n=10). Results: Cholecalciferol at 10 −7 M increased the proportion of CD4 + CD38 + and CD8 + CD38 + cells, and decreased CD8 + HLA-DR + cells. As co-expression, it increased the CD38 + HLA-DR − and decreased CD38 − HLA-DR + subpopulations in both CD4 + and CD8 + T-cells, and decreased CD4 + CD38 − HLA-DR − and CD8 + CD38 + HLA-DR + ; whereas both calcidiol concentrations decreased the proliferation of CD38 − HLA-DR − and CD38 − HLA-DR + subpopulations. Both forms of VitD increased the number of CD38 molecules per cell. In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4 + and CD8 + T-cells. Conclusion: Although no significant correlations were observed in vivo in healthy subjects, VitD treatment in vitro modulated immune activation by increasing the expression of CD38 and decreasing the proliferation of HLA-DR + and resting cells, which may correlate with improved effector and decreased proliferative capabilities. These results highlight the potential use of VitD as therapeutic strategy in immune disorders.
- 14 July 2016
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 29 (3) , 93-103
Vitamin D modulates the expression of HLA-DR and CD38 after in vitro activation of T-cells
Objective: Vitamin D (VitD) is an anti-inflammatory hormone; however, some evidence shows that VitD may induce the expression of activation markers, such as CD38 and HLA-DR. We explored its effect on the expression of these markers on CD4 + and CD8 + T-cells in vitro, and their potential correlations in vivo. Materials and methods: CD38 and HLA-DR expression was measured by flow cytometry in PHA/IL-2-activated mononuclear cells cultured under VitD precursors: three cholecalciferol (10 −11 M, 10 −9 M, 10 −7 M; n=11) and two calcidiol (40 ng/mL, 80 ng/mL; n=9) concentrations. The correlation between the expression of these markers in freshly isolated blood cells and serum levels of calcidiol was also explored (n=10). Results: Cholecalciferol at 10 −7 M increased the proportion of CD4 + CD38 + and CD8 + CD38 + cells, and decreased CD8 + HLA-DR + cells. As co-expression, it increased the CD38 + HLA-DR − and decreased CD38 − HLA-DR + subpopulations in both CD4 + and CD8 + T-cells, and decreased CD4 + CD38 − HLA-DR − and CD8 + CD38 + HLA-DR + ; whereas both calcidiol concentrations decreased the proliferation of CD38 − HLA-DR − and CD38 − HLA-DR + subpopulations. Both forms of VitD increased the number of CD38 molecules per cell. In contrast, there was a positive but non-significant correlation between serum calcidiol levels and the expression of CD38 and HLA-DR in CD4 + and CD8 + T-cells. Conclusion: Although no significant correlations were observed in vivo in healthy subjects, VitD treatment in vitro modulated immune activation by increasing the expression of CD38 and decreasing the proliferation of HLA-DR + and resting cells, which may correlate with improved effector and decreased proliferative capabilities. These results highlight the potential use of VitD as therapeutic strategy in immune disorders.